Burlington, Mass., July 08, 2026. Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) has signed a definitive agreement to raise capital through a private placement with one institutional investor specializing in the healthcare sector. The company develops orthobiologic products aimed at the spine fusion market, and the transaction is priced at-the-market under Nasdaq listing rules.
Structure And Pricing
Under the agreement, the investor will purchase 2,112,677 common shares, with the option to receive pre-funded warrants instead. Each share (or pre-funded warrant) comes bundled with two types of additional warrants: Series F warrants covering up to 2,112,677 shares and shorter-duration Series G warrants covering the same number. The combined package is priced at $1.42.
Both warrant series can be exercised at $1.42 per share, but only after shareholders approve the issuance of the underlying stock. From that point, the Series F warrants remain valid for five years, and the Series G warrants for 18 months. In each case, the clock starts on whichever comes later: the shareholder approval date or the date the resale registration statement becomes effective.
The deal is scheduled to close around July 9, 2026, pending standard closing requirements. H.C. Wainwright & Co. serves as sole placement agent.
How The Company Plans To Deploy The Capital
Before fees and expenses, the placement is expected to bring in roughly $3.0 million. Should investors exercise every Series F and Series G warrant for cash, Bone Biologics could collect another $6.0 million, though there is no guarantee any warrants will be exercised or that the company will ever receive those funds.
Management plans to direct the net proceeds toward clinical trial funding, upkeep and expansion of its patent estate, working capital, and general corporate needs.
Securities Law Status
The transaction relies on the private placement exemption under Section 4(a)(2) of the Securities Act of 1933 and/or Regulation D. None of the securities involved, including the shares underlying the warrants, have been registered federally or at the state level.
As a result, they cannot be sold or offered within the United States unless a registration statement takes effect or another valid exemption applies. The company has committed, through a registration rights agreement, to file a resale registration statement covering these securities.
Nothing in this announcement constitutes an offer to sell or a solicitation to buy, and no sales will take place in any jurisdiction where doing so would violate local securities laws before proper registration or qualification.
About Bone Biologics
Bone Biologics works in regenerative medicine focused on bone tissue. The company is running a clinical study in Australia alongside strategic partners, building on earlier preclinical work involving the NELL-1 protein. Its lead development effort centers on a bone graft substitute for spinal fusion procedures, and it also holds rights covering trauma and osteoporosis applications.
Forward-Looking Statements
Any statements in this release that go beyond historical fact qualify as forward-looking statements. They reflect what the company currently believes and expects, and additional risks can surface at any time.
Relevant uncertainties include whether the offering closes, whether closing conditions are met, how proceeds are ultimately used, whether shareholders grant approval, whether the resale registration statement becomes effective, and whether the warrants are exercised and generate proceeds.
These statements are predictions only, and real outcomes may differ substantially due to market conditions and other factors, including the risks outlined under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the company’s Annual Report on Form 10-K for the year ended December 31, 2025, along with its other SEC filings.
Readers should not rely unduly on these statements, which apply only as of the publication date. This cautionary note falls under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bone Biologics assumes no duty to update this release after publication except where the law requires it.
